TINI 2: Total Therapy for Infants With Acute Lymphoblastic Leukemia II

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05043571` - CARTALL: Chimeric-Antigen Receptor (CAR) T-Cell Therapy for Relapsed/ Refractory T-Lineage Acute Lymphoblastic Leukaemia	Phase 1
Completed	`NCT00988013` - Intensity Modulated Total Marrow Irradiation (IM-TMI) for Advanced Hematologic Malignancies	N/A
Completed	`NCT00866749` - Augmented Berlin-Frankfurt-Munster (BFM) Therapy for Adolescent/Young Adults With Acute Lymphoblastic Leukemia or Acute Lymphoblastic Lymphoma	Phase 2
Completed	`NCT01615809` - Nebulized Amphotericin B Lipid Complex in Invasive Pulmonary Aspergillosis in Paediatric Patients With Acute Leukaemia	Phase 2
Recruiting	`NCT05993949` - Study of Brexucabtagene Autoleucel Plus Dasatinib in Adults With Acute Lymphoblastic Leukemia	Phase 1
Recruiting	`NCT05885464` - A Study Evaluating the Safety and Efficacy of BEAM-201 in Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia (T-ALL) or T-Cell Lymphoblastic Lymphoma (T-LL)	Phase 1/Phase 2
Terminated	`NCT01100658` - Effects of Methylphenidate on Attention Deficits in Childhood Cancer Survivors	N/A
Recruiting	`NCT05194397` - Exercise Training and NR Supplementation Trial to Improve Fitness in AYA HCT Survivors	Phase 2
Completed	`NCT00388531` - Depocyte in the Treatment of CNS Relapse in Patients With Lymphoblastic Leucemia or Very Aggressive Lymphoma	Phase 2
Completed	`NCT00354120` - Thymoglobuline Versus Alemtuzumab in Patients Undergoing Allogeneic Transplant	Phase 2/Phase 3
Recruiting	`NCT04747912` - Study of Chemotherapy-Free Induction Regimen for Ph+ Acute Lymphoblastic Leukemia With Inotuzumab Ozogamicin (InO)	Phase 2
Recruiting	`NCT05648019` - CD19-Directed Chimeric Antigen Receptor (CAR) T-Cell Therapy for Relapsed/Refractory B-Lineage Leukaemia / Lymphoma - A Feasibility Protocol	Phase 2
Completed	`NCT03328104` - Everolimus in Combination With Nelarabine, Cyclophosphamide and Etoposide in Lymphoblastic Leukemia/Lymphoma	Phase 1
Recruiting	`NCT05429905` - Dual Anti-CD22/CD19 Chimeric Antigen Receptor-directed T Cells (CART2219.1) for Relapsed Refractory B-Lineage Leukaemia	Phase 1/Phase 2
Terminated	`NCT00776373` - Rapamycin in With High-Dose Etoposide and Cytarabine in Relapsed/Refractory Aggressive Lymphoid Malignancies	Phase 1/Phase 2
Not yet recruiting	`NCT05664230` - Efficacy of Osteopathic Treatment on the Side Effects of Curative Treatments of Lymphoblastic Leukemia in Pediatrics
Recruiting	`NCT03564704` - Precision Diagnosis Directing HDACi Chidamide Target Therapy for Adult T-LBL/ALL	Phase 2/Phase 3
Completed	`NCT04145531` - An Open-Label Study of JZP-458 (RC-P) in Patients With Acute Lymphoblastic Leukemia (ALL)/Lymphoblastic Lymphoma (LBL)	Phase 2/Phase 3
Not yet recruiting	`NCT06175702` - Treatment Protocol for Newky Diagnosed Adult Ph Positive ALL
Terminated	`NCT00967343` - Efficacy and Safety of a Donor Lymphocyte Preparation Depleted of Functional Host Alloreactive T-cells (ATIR) in Patients Undergoing a Peripheral Blood Stem Cell Transplant From a Related, Haploidentical Donor	Phase 2/Phase 3

NCT number	NCT05848687
Study type	Interventional
Source	Stanford University
Contact	Tanja A Gruber, MD, PhD
Phone	650 723 5535
Email	tagruber@stanford.edu
Status	Recruiting
Phase	Phase 1/Phase 2
Start date	November 3, 2023
Completion date	December 2033

TINI 2: Total Therapy for Infants With Acute Lymphoblastic Leukemia II

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms